Report

Global Gout Therapeutics Market is Segmented by Drug class type (Antihyperuricemic Agents, Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Colchicine, Other Drug Classes); by Application type (Acute Gout and Chronic Gout), Regional Forecasts 2021-2027

  • Publish Date: Mar,2022
  • Report ID: QI037
  • Page : 250
  • Report Type : PDF (Email)
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Gout Therapeutic Market, by region, 2019-2027 (USD Billion)
1.2.2. Gout Therapeutic Market, by Drug Class type, 2019-2027 (USD Billion)
1.2.3. Gout Therapeutic Market, by Application type, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Gout Therapeutic Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Gout Therapeutic Market Dynamics
3.1. Gout Therapeutic Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Growing Adoption of Biologics and Increasing R&D
3.1.1.2. Rising Prevalence of Gout with Increasing Alcohol Consumption
3.1.2. Market Restraint
3.1.2.1. Changing lifestyles and high purine diet
3.1.2.2. Rising patient pool
3.1.3. Market Opportunities
3.1.3.1. Potential side-effects of most existing gout therapeutic drugs
3.1.3.2. high indirect costs for therapy
Chapter 4. Global Gout Therapeutic Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Gout Therapeutic Market, by Drug Class type
5.1. Market Snapshot
5.2. Global Gout Therapeutic Market by Drug Class type, Performance - Potential Analysis
5.3. Global Gout Therapeutic Market Estimates & Forecasts by Drug Class type 2018-2027 (USD Billion)
5.4. Gout Therapeutic Market, Sub Segment Analysis
5.4.1. Antihyperuricemic Agents
5.4.2. Non-steroidal Anti-inflammatory Drugs
5.4.3. Corticosteroids
5.4.4. Colchicine
5.4.5. Other Drug Classes
Chapter 6. Global Gout Therapeutic Market, by Application type
6.1. Market Snapshot
6.2. Global Gout Therapeutic Market by Application type, Performance - Potential Analysis
6.3. Global Gout Therapeutic Market Estimates & Forecasts by Application type 2018-2027 (USD Billion)
6.4. Gout Therapeutic Market, Sub Segment Analysis
6.4.1. Acute Gout
6.4.2. Chronic Gout
Chapter 7. Global Gout Therapeutic Market, Regional Analysis
7.1. Gout Therapeutic Market, Regional Market Snapshot
7.2. North America Gout Therapeutic Market
7.2.1. U.S. Gout Therapeutic Market
7.2.1.1. Drug Class breakdown estimates & forecasts, 2018-2027
7.2.1.2. Application type breakdown estimates & forecasts, 2018-2027
7.2.2. Canada Gout Therapeutic Market
7.3. Europe Gout Therapeutic Market Snapshot
7.3.1. U.K. Gout Therapeutic Market
7.3.2. Germany Gout Therapeutic Market
7.3.3. France Gout Therapeutic Market
7.3.4. Spain Gout Therapeutic Market
7.3.5. Italy Gout Therapeutic Market
7.3.6. Rest of Europe Gout Therapeutic Market
7.4. Asia-Pacific Gout Therapeutic Market Snapshot
7.4.1. China Gout Therapeutic Market
7.4.2. India Gout Therapeutic Market
7.4.3. Japan Gout Therapeutic Market
7.4.4. Australia Gout Therapeutic Market
7.4.5. South Korea Gout Therapeutic Market
7.4.6. Rest of Asia Pacific Gout Therapeutic Market
7.5. Latin America Gout Therapeutic Market Snapshot
7.5.1. Brazil Gout Therapeutic Market
7.5.2. Mexico Gout Therapeutic Market
7.6. Rest of The World Gout Therapeutic Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Lannett Company, Inc
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. Boehringer Ingelheim
8.2.3. GlaxoSmithKline PLC
8.2.4. Horizon Therapeutic Plc
8.2.5. Mylan NV
8.2.6. Novartis International AG
8.2.7. Regeneron Therapeutical
8.2.8. Takeda Pharmaceutical company Ltd
8.2.9. Teijin Pharma Ltd.
8.2.10. Romeg Therapeutics, LLC.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption